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specific research questions. Results: We identified 327 national or regional general 
oncology registries. Almost each country has databases collecting information on 
diagnosis and survival data, but databases collecting information on treatment and 
response to treatment are rare. Interviews revealed that medical records typically 
collect detailed information on diagnosis, treatment and response, although specific 
details vary per country. ConClusions: The method tested represents a practical 
guide for identifying and assessing available RWE-sources. Patient-registries con-
taining detailed data are good sources for RWE gathering, but in countries without 
such registries, data collection from clinical practice is still a feasible alternative 
for RWE collection
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objeCtives: To understand the early lifecycle management strategies of inno-
vative oncology immunotherapies, specifically the PD-1 drugs pembrolizumab 
(Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb), for application 
across disease areas. Methods: Targeted secondary research using combina-
tions of key words (‘PD-1’, ‘Keytruda’, ‘Opdivo’, ‘FDA’, ‘Pembrolizumab’, ‘Nivolumab’, 
‘Approval’, ‘Immuno-oncology’) identified source literature, which was abstracted 
and analyzed qualitatively. Key themes were discussed in a consensus meeting and 
implications of findings were theorized. Results: Several lifecycle management 
strategies were identified from secondary research, including: indication expansion, 
patient segmentation using biomarkers, and combining with other drug treatments. 
Pembrolizumab and nivolumab - both holders of Breakthrough Therapy status - 
received accelerated approval from the FDA for advanced melanoma in late 2014. 
Nivolumab subsequently received approval for NSCLC in March 2015, while pem-
brolizumab was under FDA Priority Review for the same indication as of June 2015. 
Nivolumab is also under Priority Review in combination with ipilimumab (Yervoy, 
Bristol-Myers Squibb) for melanoma. Both PD-1 therapies are in numerous clinical 
trials for further oncology indications, and pembrolizumab has shown improved 
response rates in patients with a specific genetic biomarker, which is predictive of 
response across a range of cancers. ConClusions: In highly competitive therapeu-
tic areas, manufacturers of innovative products need to consider multiple strategies 
for creating, maintaining, protecting and increasing product value. Demonstration of 
substantial improvements in clinical efficacy over the standard of care in one indi-
cation is not sufficient for ‘success’. Earlier access through the FDA’s Breakthrough 
Therapy designation and accelerated approval program is critical for first-to-market 
entrants. Expansion into both larger and more niche indications offers a comple-
mentary access strategy, while gaining a foothold in combination regimens pro-
vides opportunity for further product differentiation. Similar considerations apply 
to therapies that can treat several indications within a broader disease area.
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objeCtives: Observational studies can be useful to fill in gaps of randomized stud-
ies or when these cannot be conducted. Aim of this study was the assessment of 
available real world evidence (RWE) in oncology and the identification of research 
gaps for Germany. Methods: A systematic literature search was conducted to 
evaluate the status quo of RWE in the field of oncology. Key words identifying 
health services research in combination with oncology in Germany were used in 
a search performed in the DIMDI (German Institute of Medical Documentation 
and Information) meta-database including all years up to 2015. The selected pub-
lications were classified by type of RWE study and further categorized by cancer 
types. Results: In total, 80 publications were included and stratified by RWE 
approach and cancer type. Nine RWE categories were determined, including cancer 
registries, registry-linked data, health care claims, inpatient and outpatient data, 
and surveys. Most observational studies (56%) assessed oncologic health care by 
conducting surveys, followed by cancer registries (10%) and claims data (9%). Overall, 
32 studies evaluated cancer in general, breast cancer was assessed in 15 studies, 
whereas 4 addressed prostate cancer, with remaining publications addressing other 
cancer types. Most observational studies were published in 2011 (18%). Assessments 
with cancer registries were published as of 2011, whereas there were no studies 
with claims data from 2012-2014. Specific care and treatment of cancer patients, 
including palliative care was considered in 23 publications. Almost all cancer types 
were assessed, except lymphoid and hematopoietic neoplasms. Moreover, claims 
data were hardly used. For surveys, it can be noted that the use increased from 2005 
onwards. ConClusions: The available evidence shows that RWE data in oncology 
has not yet reached its potential to supplement randomized studies. Research gaps 
exist in terms of RWE treatment with new concepts and drugs.
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objeCtives: Breast cancer has important economic, psychological and social 
impact for the patients, their families and the health system. Our aim was to 
record the emotional journey of patients with breast cancer during the different 
treatment stages. Methods: A qualitative study was performed in December 
2014, using a semi-structured interview guide. Participants were recruited through 
a patients’ organization. Women with a diagnosis of primary or secondary breast 
Ca after 2011, residing in Athens who had completed treatment were eligible 
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objeCtives: To understand how 11 pricing & reimbursement (P&R) processes 
assess the value of innovative medicines to provide sustainable and timely 
patient access. bACkgRound: In November 2014, the UK Minister for Life 
Sciences announced the Innovative Medicines and Medical Technology Review 
to consult various stakeholders on how to improve access to medicines in 
England. Methods: Eleven processes were analysed focusing on oncology: 
Australia, Belgium, Canada, England, France, Germany, Italy, Netherlands, New 
Zealand, Scotland and Sweden. The decision-making process was split into eight 
steps: regulatory approval, health technology assessment, appraisal, reimburse-
ment decision, price negotiations, decision enforcement, routine access and 
later-stage reassessments. Data collection was based on the Hutton and Allen 
frameworks [Hutton et al. 2006] [Allen et al. 2013]. The analysis relies on a pro-
posed definition of patient-centricity, assuming that value creation for patients 
should determine the reward of other stakeholders [Porter 2010]. It was designed 
to assess how each process delivers value for patients (equity of access, fulfil-
ment of societal needs, fast access to innovation), the healthcare system (eco-
nomic and financial sustainability) and the research-based industry (innovation 
reward). Results: In patient-centric systems, the reimbursement decision tends 
to be solely based on the therapeutic value of the medicine. Cost considerations 
are generally addressed by price negotiations in a second stage. Other processes 
focus more on cost-effectiveness or budget impact (potentially with thresholds), 
which drives the reimbursement decision alongside clinical effectiveness; pricing 
and reimbursement are decided jointly. The English and Scottish processes are the 
only ones that have no price negotiations with manufacturers. ConClusions: 
Patient-centric P&R processes succeed in delivering value to major stakeholders 
by first deciding on the reimbursement status of a new medicine based on its 
value to patients. They then independently negotiate a price with manufacturers 
to ensure economic and financial sustainability for the healthcare system and 
innovation reward for the manufacturer.
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objeCtives: Research findings point to the existence of delays in symptom rec-
ognition, diagnosis and treatment of breast cancer. The present study aimed at 
identifying reasons for delay in breast cancer diagnosis in Greece. Methods: 
A qualitative study was performed in December 2014, using a semi-structured 
interview guide. Recruitment was performed through a patients’ organization. 
Women with a diagnosis of primary or secondary breast Ca after 2011, residing 
in Athens, and who had completed treatment were eligible for the study. The 
interviews were recorded with participants’ written consent and were transcribed 
and content analyzed using a model of patient and provider delay. Results: 23 
women participated. Delays were detected in all intervals of the patient pathway. 
Although most participants performed annual breast cancer screening tests, some 
women had not undergone screening the year previous to their diagnosis due to 
financial and personal reasons. In the majority of cases women were symptomatic, 
however, there were difficulties in appraising symptoms as related to illness. The 
presence of a breast lump is the main symptom that caused non-delayers to seek 
medical attention. Women who had delayed consulting with a physician despite 
having found a breast lump gave the following reasons: misattributing their symp-
tom to benign conditions or breast-feeding, having competing priorities such as 
family and other personal health problems, depression or denial and financial 
barriers to visiting a specialist. The study also identified delays in diagnosis attrib-
uted to the healthcare providers, as in some cases physician(s) did not suspect 
malignancy. ConClusions: Delayed diagnosis of breast cancer among women 
participating in the study is attributed to both patient and provider behavior. Our 
findings indicate that raising awareness and educating both patients and health 
providers is important. However, further research is necessary to identify the 
extent of the problem and confirm these results.
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objeCtives: Real-world evidence (RWE) can be gathered from various sources, 
including existing registries, claims data or medical records. The challenge is select-
ing the best RWE-source for answering specific research questions. As data sources 
collect different data elements, the best RWE collection approach for gathering 
the necessary data will differ per country. The objective was to test a systematic 
approach for identifying and selecting RWE-sources per indication. Methods: 
Our approach consisted of two workstreams: assessment of existing RWE-sources 
and inventory of data elements collected in clinical practice. We selected oncol-
ogy as test indication and the European Union as the target area. The first step of 
workstream one is a targeted literature search to identify RWE-sources. Database 
owners were surveyed on their data. A scoring algorithm was developed to prioritize 
RWE-sources on the number and type of relevant data elements. Finally, the most 
promising databases for answering specific research questions were selected based 
on their score and collaboration possibilities. For workstream two, a small sample 
of practicing physicians were interviewed on what data is routinely recorded in 
clinical practice. The results from the two workstreams were combined to analyse 
per country which collection approach is optimal for RWE generation for answering 
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objeCtives: As the emphasis on value of oncology agents grows, ASCO has released 
a framework proposing to evaluate the net health benefit of such therapies. This 
study aims to evaluate the application of the ASCO framework for all recently 
approved oncology therapies, including barriers and challenges that may be encoun-
tered. Methods: Oncology drugs approved from January 2013 to May 2015 (N= 19) 
were obtained from the FDA website. Palliative therapies were excluded. Registrational 
trials (N= 31) for the corresponding drugs were identified from peer-reviewed publica-
tions. The Net Health Benefit (NHB) score worksheet was completed for each clinical 
trial as outlined in the ASCO advanced disease framework using Overall Survival (OS), 
Progression-Free Survival (PFS), Response Rate (RR), Toxicity, Palliation, and Treatment-
Free Interval. Issues encountered were catalogued for review. Results: 1 of 31 clinical 
trials was excluded due to lack of publication in peer-reviewed journals. An additional 
9 trials were excluded due to non-randomized trial design, resulting in 22 trials cor-
responding to 16 drugs. OS data was used for scoring in 59% of the remaining trials. 
PFS was used in 27% of the trials, and RR in 14% of the trials. Toxicity data was scored 
in 95% of the trials, palliation data in 77% of trials, and treatment-free interval data 
in 95% of the trials. The most common scoring issues encountered included median 
OS or PFS not reached (8/22) and incomplete palliation or treatment-free interval 
data (5/22). ConClusions: Lack of peer-reviewed publications, non-randomized 
trial designs, and requisite clinical data resulted in methodological challenges that 
deterred application of the ASCO framework for recent oncology drugs. Lack of appro-
priate data may result in lower scores than could be recognized from the available 
evidence at time of market authorization.
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objeCtives: France is one of the European countries that spends the most on oncol-
ogy drugs. In the context of a cost-constraint environment, Health Authorities highly 
scrutinize market access pathways for potentially costly medicines. This study aimed 
to conduct a review of the Transparency Committee (CT) opinions of antineoplas-
tic drugs indicated for the treatment of solid tumours to assess current trends in 
French health technology assessment (HTA), to confront experts with outcomes of 
this review and discuss foreseen challenges for HTA of future antineoplastic medi-
cines in France. Methods: A review of CT opinions issued for all antineoplastic drugs 
indicated in the treatment of solid tumours and approved between 2009 and 2014 
was performed to assess current trends in French HTA. An expert board consultation 
was also conducted to capture critical issues on the future of antineoplastic drugs 
HTA. Results: Thirty-one drugs indicated for the treatment of solid tumors were 
identified. Targeted therapies represented 77% of all drugs. Initial CT assessments 
were available for 26 drugs. Efficacy /safety ratio predicted actual benefit (SMR), but 
not improvement in actual benefit (ASMR) ratings. Early access scheme for innova-
tive medicines did not impact ASMR score. Four key items in CT assessment were 
identified: (1) Clinical trial methodology; (2) Acceptance of progression-free survival 
as a valuable endpoint; (3) Transferability of clinical trials in clinical practice; (4) Lack 
of predictability of CT decisions. Experts pointed out the important development of 
personalized medicine in oncology raising many challenges in terms of strategic posi-
tioning, ethics and clinical trial design, to generate information expected from HTA 
perspective. ConClusions: French system remains committed to its values and phi-
losophy (access of all innovations for everybody) which are threatened by the increas-
ing launch of innovative therapies and budget constraint. French HTA analysis decision 
model will have to evolve to cope with new challenges raised by oncology drugs.
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objeCtives: To identify similarities and differences in HTA decision-making pro-
cesses and outcomes, and explore the criteria driving these decisions in different 
settings analysing a sample of cancer drugs. Methods: This study applied a vali-
dated methodological framework built on a mixed methods approach to system-
atically compare HTA recommendations for a sample of 15 cancer drugs in four 
countries (England, Scotland, Sweden and France). All decision-making criteria were 
identified and compared at each stage of the decision-making process: the evidence 
appraised, its interpretation and influence on the final decision. Qualitative data 
collection and analysis was conducted using the NVivo software. Results: Across 
the sample, the same primary trials were generally appraised to determine the 
treatment’s clinical efficacy (93% common to all). From the same trials, heteroge-
neity was seen in the subgroup analyses (nsubgroupNICE= 25, nsubgroupHAS = 15, 
nsubgroupSMC= 11, nsubgroupTLV= 7) and number of endpoints considered (nend-
pointsNICE= 149, nendpointsHAS 100, nendpointsSMC= 105, nendpointsTLV= 15). All 
the primary trials were phase III, 57% of which were open-label. Direct comparators 
were the most commonly used (37%), the remainder being placebo (28%), standard 
care (13%), none (13%) and drugs in sequence (8%). The economic trials presented 
were the same across the agencies, where 53% used the same direct comparator. 
When interpreting the same trials, NICE raised the highest number of concerns 
(nuncertainNICE= 94 uncertainties), of which 76% were addressed by various means 
(74% by stakeholder input). SMC, HAS and TLV raised a lower number of uncer-
tainties with fewer being addressed (16% of nuncertainSMC= 80, 8% of nuncertain-
HAS= 38, and 9% of nuncertainTLV= 11). ConClusions: This study enables to better 
understand the reasons for differences across countries, and whether we can learn 
from the different ways seen to assess value in different settings. Identifying those 
for the study. The interviews were recorded after participants’ written consent 
and were transcribed and content analyzed. Results: 23 women participated. 
Fear, panic, anger, and anxiety were the main feelings during the diagnosis. 
Chemotherapies were perceived as the most painful part of the treatment both 
physically and emotionally. Mastectomy and hair loss changed their image radi-
cally. Their husband and friends were the two most important sources of support 
and they felt that their relationships became stronger during the disease. The 
disease had a severe impact on patients’ families as well and a major concern 
among the participants was their children. At the time of the study, women evalu-
ated their experience positively. They attribute their disease to their previous 
way of life and they perceive it as a chance to move forward and put themselves 
first. During their journey they felt the need for psychological support but this 
was not always feasible due to economic barriers and lack of such services in the 
hospitals. ConClusions: Breast cancer diagnosis is the beginning of a long and 
painful journey that brings changes to patients’ life. At the end however, most 
patients seem to embrace their disease which becomes part of their identity. 
Professional psychological support is necessary in all stages and needs to be part 
of the treatment process in Greece.
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objeCtives: To identify decisions by the SMC using the PACE process since the 
scheme was introduced and identify issues that influence a successful out-
come. Methods: Assessments that used the PACE process were identified from 
SMC briefing notes between May 2014 and June 2015. Key points expressed were 
classified into clinical issues or added value to the patient or carers. Results: 
Twenty assessments were identified that used the PACE process: 17 in oncology 
indications and one each in hypertension, infection in cystic fibrosis, and myelofi-
brosis/splenomegaly. Ten were accepted (seven with a patient access scheme [PAS]) 
– three that met orphan criteria, one that met end-of-life criteria, and six that met 
both. Five products were accepted with restrictions (four with a PAS) and five were 
rejected (one with a PAS). All assessments discussed clinical issues, including 
health-related benefits (17/20), health-related quality of life (HRQL) benefit related 
to symptoms (13/20), and reduction in adverse events (11/20). Sixteen provided 
data on the severity of the condition (impact on patients, carers and families, 
and/or assessment of severity); 9 characterized the unmet need; 13 considered 
the most appropriate position for the medicine in the pathway of care and/or 
identified specific patient groups. Seven assessments argued for added value to 
patients (convenience of treatment) and value to patient’s family and carers in 
terms of impact on family life (6), requirements for carers (2), and carers’ ability 
to work (1). ConClusions: PACE assessments to date have largely focused on 
clinical issues and patient’s quality of life, with limited attention as yet to the 
benefit to patients’ families/carers. PACE appears to be meeting the SMC’s objec-
tive of providing a forum for patients and clinicians to present arguments regard-
ing the wider benefits of a drug that may not be easily captured in the standard 
assessment process.
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objeCtives: This study estimates the burden of breast cancer (BC) on population 
health in Portugal in 2013. Methods: The impact on health status was measured 
using the Disability Adjusted Life Years (DALYs). Years Lost due to Disability (YLD) 
were estimated following Kruijshaar and Barendreght (2004) and the European 
Disability Weights project. This model separates the BC patients into 5 different 
pathways: 1) survivors undergoing mastectomy or 2) breast-conserving surgery, 
3) non-survivors undergoing mastectomy or 4) breast conserving therapy, or 5) 
patients diagnosed with non-operable or disseminated disease. The model uses an 
incidence perspective giving to each pathway a different sequence of health states 
with specific disutility weights. Data from the Portuguese National and Regional 
Cancer Registries was used to estimate the incidence of BC in Portugal. Portuguese 
DRG Database was queried in order to identify incident cases undergoing surgery. 
The average total disease duration by age groups was approximated using DisMod II 
software. The Years of Life Lost (YLL) due to BC premature mortality were calculated 
based on data from the Portuguese Institute of Statistics using a social weighting 
function which places a greater value on a year lived as a young adult. Results: 
In Portugal 6.938 new cases of female BC were estimated. A total 1,646 deaths were 
caused by BC in the same year, which corresponds to 3.1% of the total female deaths 
in Portugal. The YLL caused by BC in 2013 totaled 13,425 representing 6.1% of YLL in 
the female population of the country. For 2013 the YLD estimated were 11,368. The 
total disease burden attributable to female BC is thus estimated at 24,793 DALY or 
453 DALY/100,000 women. ConClusions: Breast cancer is an important cause of 
disease burden for Portuguese women and should be an important target for health 
policy interventions.
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